Professor Jonas Nillson
Jonas Nilsson moved to Sahlgrenska Cancer Center at University of Gothenburg, Sweden, 2011. Here, he founded a translational research group together with clinicans at the Sahlgrenska University Hospital. The group aims to identify new treatment options for melanoma patients based on translational and clinical research. Focus lies on understanding the genetics of the disease and creating humanized animal models of melanoma (PDX) for use in translational research (Einarsdottir et al., Oncotarget 2014; Gad et al., Nature 2014; Xue et al., Nature Medicine 2107; Jespersen/Lindberg et al., Nature Communications 2017; Nilsson et al., Nature, 2018; Forsberg et al., Cancer Research 2019). Recently, the utility of their unique immune-PDX model has been tested in other diagnoses than melanoma incl breast cancer (unpublished). Focus of the group is also on investigator-initiated clinical trials where Dr Nilsson currently manages the translational effort of the SCANDIUM and the PEMDAC clinical trials for ocular/uveal melanoma patients. Overall, Dr Nilsson has authored over 70 publications many of which in leading journals. He is an Investigator of the Swedish Cancer Society since 2007 and reached status of Full Professor in Experimental Cancer Surgery 2015. He is the Director of Sahlgrenska Cancer Center since 2018.